Cargando…

Genetic Features of HIV-1 Integrase Sub-Subtype A6 Predominant in Russia and Predicted Susceptibility to INSTIs

The increasing use of the integrase strand transfer inhibitor (INSTI) class for the treatment of HIV-infection has pointed to the importance of analyzing the features of HIV-1 subtypes for an improved understanding of viral genetic variability in the occurrence of drug resistance (DR). In this study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kirichenko, Alina, Lapovok, Ilya, Baryshev, Pavel, van de Vijver, David A. M. C., van Kampen, Jeroen J. A., Boucher, Charles A. B., Paraskevis, Dimitrios, Kireev, Dmitry
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472261/ https://www.ncbi.nlm.nih.gov/pubmed/32752001 http://dx.doi.org/10.3390/v12080838

Ejemplares similares

2492. Differences between Individuals Currently Taking Integrase Inhibitor (INSTI)-based Therapy and Those Not Taking INSTIs in the Era of INSTIs as Recommended First-line Therapy
por: Monroe, Anne K, et al.
Publicado: (2019)

Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV
por: Dow, Dorothy E., et al.
Publicado: (2014)

Prevalence of Integrase Strand Transfer Inhibitors (INSTI) Resistance Mutations in Taiwan
por: Chang, Sui-Yuan, et al.
Publicado: (2016)

Molecular epidemiology of HIV-1 in Oryol Oblast, Russia
por: Safina, Ksenia R, et al.
Publicado: (2022)

A computational overview of integrase strand transfer inhibitors (INSTIs) against emerging and evolving drug-resistant HIV-1 integrase mutants
por: Sayyed, Sharif Karim, et al.
Publicado: (2023)

1566. Determinants associated with weight gain among persons with HIV who switch to integrase strand transfer inhibitors (INSTI)
por: Cutshaw, Melissa Klein, et al.
Publicado: (2023)

Prevalence of resistance to integrase strand-transfer inhibitors (INSTIs) among untreated HIV-1 infected patients in Morocco
por: Alaoui, Najwa, et al.
Publicado: (2018)

Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort
por: Focà, Emanuele, et al.
Publicado: (2021)

A clinical review of HIV integrase strand transfer inhibitors (INSTIs) for the prevention and treatment of HIV-1 infection
por: Zhao, Alexa Vyain, et al.
Publicado: (2022)

HIV-1 Drug Resistance among Treatment-Naïve Patients in Russia: Analysis of the National Database, 2006–2022
por: Kirichenko, Alina, et al.
Publicado: (2023)

1043. The impact of integrase strand transfer inhibitors (InSTIs) on weight gain among adults with HIV in clinical care
por: Thatipelli, Sneha, et al.
Publicado: (2020)

META-INSTI: metabolic adverse events following integrase strand transfer inhibitor administration in spontaneous adverse event reports
por: Murray, Milena M, et al.
Publicado: (2023)

A11 The 1988 Elista outbreak and the epidemiology of HIV subtype G in Russia
por: Serova, Ekaterina, et al.
Publicado: (2018)

106. META-INSTI: Metabolic Adverse Events Following Integrase Strand Transfer Inhibitor Administration in Spontaneous Adverse Event Reports
por: Murray, Milena M, et al.
Publicado: (2020)

GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants
por: Aoki, Manabu, et al.
Publicado: (2023)

A25 Analysis of non-structural genes subtype A1 HIV-1 circulating in Russia
por: Gromov, K, et al.
Publicado: (2018)

Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017–2018 and 2020–2021 following a WHO Survey
por: Kirichenko, Alina, et al.
Publicado: (2022)

Selected CNS Outcomes Among INSTI Antiretrovirals
por: Wohl, David, et al.
Publicado: (2017)

The Emergence of Resistance Under Firstline INSTI Regimens
por: Xie, Zhiman, et al.
Publicado: (2022)

Association between integrase strand transfer inhibitor (INSTIs) use with insulin resistance and incident diabetes mellitus in persons living with HIV: A systematic review and meta-analysis protocol
por: Mulindwa, Frank, et al.
Publicado: (2022)

1563. Incidence of Errors in an INSTI-Based Era: A Comparison of Error Rates Between Single Versus Multiple Tablet INSTI-Based Regimens in the Inpatient Setting
por: Blackmon, Kayla, et al.
Publicado: (2023)

Molecular Epidemiology of HIV-1 Subtype G in the Russian Federation
por: Murzakova, Anastasia, et al.
Publicado: (2019)

Limited emergence of resistance to integrase strand transfer inhibitors (INSTIs) in ART-experienced participants failing dolutegravir-based antiretroviral therapy: a cross-sectional analysis of a Northeast Nigerian cohort
por: Abdullahi, Adam, et al.
Publicado: (2023)

Targeted HCV core antigen monitoring among HIV-positive men who have sex with men is cost-saving
por: Popping, Stephanie, et al.
Publicado: (2019)

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro
por: Acosta, Rima K., et al.
Publicado: (2022)

High prevalence of integrase mutation L74I in West African HIV-1 subtypes prior to integrase inhibitor treatment
por: El Bouzidi, Kate, et al.
Publicado: (2020)

Comparative biochemical analysis of HIV-1 subtype B and C integrase enzymes
por: Bar-Magen, Tamara, et al.
Publicado: (2009)

888. In Vitro Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
por: Acosta, Rima K, et al.
Publicado: (2021)

Genetic characterization of an isolate of HIV type 1 AG recombinant form circulating in Siberia, Russia
por: Baryshev, P. B., et al.
Publicado: (2012)

In Silico and In Vitro Comparison of HIV-1 Subtypes B and CRF02_AG Integrases Susceptibility to Integrase Strand Transfer Inhibitors
por: Ni, Xiaoju, et al.
Publicado: (2012)

Performance and usability evaluation of the INSTI HIV self-test in Kenya for qualitative detection of antibodies to HIV
por: Bwana, Priska, et al.
Publicado: (2018)

2508. Virologic Suppression in Patients Switched to BIC/TAF/FTC with Baseline NRTI and/or INSTI Resistance
por: Natali, Kayla M, et al.
Publicado: (2019)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV
por: McLaughlin, Taryn, et al.
Publicado: (2023)

Dual inhibition of HIV-1 replication by integrase-LEDGF allosteric inhibitors is predominant at the post-integration stage
por: Le Rouzic, Erwann, et al.
Publicado: (2013)

Prevalence of HIV-1 drug resistance in Eastern European and Central Asian countries
por: Kirichenko, Alina, et al.
Publicado: (2022)

Structural Implications of Genotypic Variations in HIV-1 Integrase From Diverse Subtypes
por: Rogers, Leonard, et al.
Publicado: (2018)

Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer
por: Yang, Jing, et al.
Publicado: (2022)

Comparative biochemical analysis of wildtype and drug resistant HIV-1 integrase subtypes B and C
por: Bar-Magen, Tamara, et al.
Publicado: (2009)

Application of Space Technologies Aimed at Proprioceptive Correction in Terrestrial Medicine in Russia
por: Motanova, Eugenia, et al.
Publicado: (2022)

HIV-1 Integrase Inhibitors with Modifications That Affect Their Potencies against Drug Resistant Integrase Mutants
por: Smith, Steven J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ga08tp3aa002t3uf23m0n4r8de